Laboratory Of Neuroproteomics Unicamp Endereco

1. Laboratory Of Neuroproteomics Unicamp Endereco Student

Laboratory of Human Cytogenetics and Cytogenomics Research activities: the Human Cytogenetics Laboratory began operating shortly after the creation of the Department of Medical Genetics by Professor Dr. Bernardo Beiguelman, which took place with the founding of the Faculty of Medical Sciences in 1963.

Oligodendrocytes are a type of neuroglia that provide trophic support and insulation to axons in the central nervous system. The genesis and maturation of oligodendrocytes are essential processes for myelination and the course of CNS development. Using ion mobility‐enhanced, data‐independent acquisitions and 2D‐nanoUPLC fractionation operating at nanoscale flow rates, we established a comprehensive data set of proteins expressed by the human oligodendroglia cell line MO3.13. The final dataset incorporating all fractions comprised 223 531 identified peptides assigned to 10 390 protein hits, an improvement of 4.5 times on identified proteins described previously by our group using the same cell line. Identified proteins play pivotal roles in many biological processes such as cell growth and development and energy metabolism, providing a rich resource for future studies on oligodendrocyte development, myelination, axonal support, and the regulation of such process. Our results can help further studies that use MO3.13 cells as a tool of investigation, not only in relation to oligodendrocyte maturation, but also to diseases that have oligodendrocytes as key players.

All MS data have been deposited in the ProteomeXchange with identifier PXD004696.

Laboratory Of Neuroproteomics Unicamp Endereco Student

.Part of thebook series (MIMB, volume 1546) AbstractIn the case of major psychiatric disorders such as schizophrenia, shortcomings in the conversion of scientific discoveries into newer and safer treatment options has led to a loss of confidence and precipitated a crisis for large pharmaceutical companies. This chapter describes how incorporation of multiplex biomarker approaches into the clinical pipeline can lead to better patient characterization, delivery of novel treatment approaches and help to renew efforts in this important area. The development of specific biomarker test panels for disease prediction should facilitate early intervention strategies, which may help to slow disease development or progression. Furthermore, the development of such tests using lab-on-a-chip and smartphone platforms will help to shift diagnosis and treatment of this major disorder into a point-of-care setting for improved patient outcomes.